Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CORONARY AND STRUCTURAL INTERVENTION

IMAGING

MECHANICAL TECHNOLOGY

CLINICAL

CARDIOGENIC SHOCK

INTERVENTIONAL

EARLY CAREER INVOLVEMENT

133 - TALES & MYSTERIES FROM THE CATH LAB

Thursday, October 24, 2024
11:00 AM – 12:00 PM PT
Room: 205-207
Early Career Involvement
Workshop Description: The annual Tales & Mysteries from the Cath Lab session will highlight relevant and critical topics applicable and highly relevant to Canada's cardiovascular community. This year, we will have two unique sessions covering coronary and structural categories that apply to general, imaging, and interventional cardiologists and cardiac surgeons.

Our first discussion area will focus on MINOCA (Myocardial Infarct with Non-Obstructive Coronary Arteries) and INOCA (Ischemia with Non-Obstructive Coronaries). This topic was selected given the ongoing diagnostic uncertainty that persists amongst general and interventional cardiologists despite advanced imaging. Cath labs across Canada have focused on bringing microvascular and CFR (coronary flow reserve) testing into routine practice to clarify diagnosis and understand treatment nuances. Using a case-based approach, the workshop will offer insight and an algorithmic approach to shed light on this clinically challenging patient population.

Our second topic will focus on current thoughts, ongoing controversies, and future directions on using AngioVac for patients with Right-sided Infective Endocarditis. Experience with the technology remains sparse in Canada but has been identified as a rapidly evolving area in the interventional cardiology landscape. Practice patterns vary across Canada; bringing timely perspectives and sharing operator experiences is crucial to its growth. Like all structural interventions, AngioVac remains heavily supported by a multidisciplinary and Heart Team approach.

Both topics will be delivered by world-class speakers and individuals who focus their practice in each field. The workshop format will allow ample time between presentations and, ultimately, for questions, discussion, and debate. A diverse panel will be available to dissect topics in further detail and provide additional unique insights throughout the workshop. The Tales & Mysteries session will challenge the Canadian cardiovascular community and remain a premier workshop at the Canadian Cardiovascular Congress in 2024.

Interactive and Engagement Activities Description: Multiple opportunities throughout the workshop will encourage audience participation, panel discussion, Q&A period, and debate. Time will be allocated for dialogue between each topic (coronary/structural). There will also be time budgeted at the end of the session for more discussion on either subject. Presenters will be mandated to use ARS in their slides to encourage ongoing audience participation throughout. Co-Chairs will moderate panel discussion and Q&A period.

Learning Objectives:

At the end of this session participants will be able to:
  • identify a contemporary algorithm for the diagnosis and management of MINOCA using a case-based approach;
  • recognize the importance of microvascular testing in the invasive diagnosis of MINOCA including CFR (coronary flow reserve) testing;
  • recognize the novel and therapeutic benefits of AngioVac as a treatment tool for patients with Right-sided infective endocarditis;
  • develop an understanding of appropriate patient selection, controversies, and future directions for AngioVac as a therapeutic entity for Right-sided infective endocarditis; and
  • recognize the value of the Heart Team approach in patients with infective endocarditis.
Disclosure(s):
Debraj Das, MD MSc FRCPC FACC: Amgen: Speaking Honorarium (Terminated, June 30, 2022); Novartis: Consultancy Board (Ongoing), Speaking Honorarium (Ongoing); Novo Nordisk: Consultancy Board (Terminated, February 28, 2024)
Janine Eckstein, MD: No financial relationships to disclose
Olga Toleva, MD: No financial relationships to disclose
Chloe Laferriere, n/a: No financial relationships to disclose
Mina Madan, MD, MHS, FRCPC, FSCAI: Medtronic Canada: Consultant (Ongoing); Novo Nordisk: Research and Clinical Trial Leadership (Ongoing)